|
Invited Speakers:
|
|
Confirmed speakers include: · Joanne Waldstreicher, MD, Chief Medical Officer, Johnson & Johnson, Pharmaceuticals· Dr Alan Barge, Vice President, Head of Clinical Oncology, AstraZeneca· Dr Colin Goddard, CEO, OSI Pharmaceuticals· Dr José Baselga, Chief, Division of Hematology/Oncology & Associate Director, Massachusetts General Hospital Cancer Center· D. Stafford O'Kelly, President, Abbott Molecular Diagnostics · Dr Christoph Lengauer, Vice President & Global Head of Oncology, Discovery Research, Sanofi-Aventis· Jean R. Slutsky, Director, Center for Outcomes & Evidence, Agency for Healthcare Research & Quality (AHRQ), US Department of Health & Human Services· Dr Rafael Amado, Vice President, Head of Solid Oncology Medicines Development, GlaxoSmithKline· Dr Naomi Aronson, Executive Director, Technology Evaluation Center (TEC), BlueCross & BlueShield Association· Roy Baynes, MD, PhD, Vice President, Global Development & Therapeutic Area Head Hematology/Oncology, Amgen, Inc· Dr Michael M. Morrissey, President of Research & Development, Exelixis, Inc· Dr Robert A. Kramer, Vice President, Oncology & Immunology Drug Discovery, Bristol-Myers Squibb· Dr Abraham Tzou, Division of Immunology & Hematology, Office of In Vitro Diagnostic Device Evaluation & Safety, The Food & Drug Administration· Kristin Borradaile, Director, Medical Affairs, CoreLab Partners, Inc· Jens Oliver Funk, MD, Senior Vice President, Merck Serono R&D, Global Head of TA Oncology, EMD Serono, Inc· Dr Jean-Pierre Bizzari, Senior Vice President, Clinical Oncology/Hematology, Celgene Corporation· Denise Deakin, President, Scimega Research· Dr David Urdal, Chief Scientific Officer, Dendreon Corporation· David Donabedian, Vice President of Strategic Alliances, US CEEDD, GlaxoSmithKline· Dr Nicholas C. Dracopoli, Vice President, Biomarkers, Centocor R&D, Johnson & Johnson· Detlev Biniszkiewicz, PhD, Global Head of Portfolio Management & Analysis, Novartis Institutes for BioMedical Research· Dr Matthew L. Meyerson, Associate Professor of Pathology, Dana-Farber Cancer Institute · Dr Stuart Lutzker, Vice President, BioOncology Exploratory Clinical Development, Genentech, Inc· Dr Nancy Simonian, CMO, Millennium: The Takeda Oncology Company· Dr Gerd Maass, Global Head, Biomarker & Pathway Analysis, Translational Research Sciences, Roche Pharma Research & Early Development· Dr Gary J. Kelloff, Special Advisor, DCTD, CIP, National Cancer Institute· Dr Stephen M. Kelsey, Executive Vice President & Chief Medical Officer, Oncology, Geron Corporation· Dr Karen Zinkewich-Peotti, Vice President, Oncology Research, UCB· Yannis Jemiai, PhD, Director of Biostatistics, Cytel Inc· Dr Mike Burgess, Head, Oncology Early Development Group, Roche· Dr Daniela S. Gerhard, Director, Office of Cancer Genomics, National Cancer Institute· Dr Rob Williams, Head of Nonclinical Operations & Chief Development Scientist, Cancer Research UK· Dr Marc Berger, Vice President, Global Health Outcomes, Eli Lilly and Company· Wayne A. Rosenkrans, Jr, PhD, Distinguished Fellow, MIT Center for Biomedical Innovation; Program in Ethics and Systems Medicine, Georgetown University; Chairman, Personalized Medicine Coalition; Vice President Strategic Consulting, Fuld and Co; Chief Scientific Advisor, Expertech Solutions; Chief Applications Officer, SciTech Strategies· Dr Jonathan Drachman, Senior Vice President, Research & Translational Medicine, Seattle Genetics· Dr Louise B. Grochow, Executive Director of Global Medical Science, AstraZeneca · Dr Markus Warmuth, Executive Director, Head of Oncology Drug Discovery, Cambridge, Novartis Institutes for BioMedical Research· Dr Timothy Yeatman, Executive Vice President, Co-Founder & Chief Scientific Officer, M2Gen· Jerald S. Schindler, Dr.P.H., Vice President, Biostatistics & Research Decision Sciences - Late Development Statistics, Merck Research Laboratories· Professor Donald A. Berry, Head, Division of Quantitative Sciences, Chairman, Department of Biostatistics & Frank T. McGraw Memorial Chair of Cancer Research, The University of Texas MD Anderson Cancer Center· Jeffrey Heilbraun, Senior Manager, Scientific Affairs, CoreLab Partners, Inc· David Weiner MD., Senior Medical Director, Head of Early Clinical Development Neurology Global Clinical Development Unit, EMD Serono, Inc.· Dr Jeffrey Helterbrand, Global Head of Biostatistics, Genentech, Inc· Dr Joan A. Lasota, Senior Director, Alliance Management, Merck & Co, Inc· Elaine Caughey, Senior Director, Business Development, Biogen Idec· Dr Yves Dubaquie, Director, Business Development & Licensing, Novartis Molecular Diagnostics· Mark R. Trusheim, Executive in Residence & Visiting Scientist, Massachusetts Institute of Technology Sloan School of Management; President, Co-Bio Consulting LLC · Dr James E. Bradner, Dana-Farber Cancer Institute
|
|